Avidity Biosciences Inc
RNAM
株式のランク
#2081
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
株価
$71.34
最終同期: 2026-03-03
時価総額
$9.84B
変化（1日）
0.00%
変化（1年）
-
国
US
取引 Avidity Biosciences Inc (RNAM)
カテゴリー
Healthcare
Avidity Biosciences Inc（RNAM）の収益
Oct 2026 時点の収益 TTM: 0
Avidity Biosciences Inc の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Avidity Biosciences Inc の収益履歴（2018 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2025 | $18.76M | 72.11% |
| 2024 | $10.90M | 13.99% |
| 2023 | $9.56M | 3.64% |
| 2022 | $9.22M | -1.09% |
| 2021 | $9.33M | 37.41% |
| 2020 | $6.79M | 192.67% |
| 2019 | $2.32M | 511.87% |
| 2018 | $379.00K | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
